<!DOCTYPE html>
<html lang="en-us">
<head>

  <meta charset="utf-8">
  <meta name="viewport" content="width=device-width, initial-scale=1">
  <meta http-equiv="X-UA-Compatible" content="IE=edge">
  <meta name="theme" content="hugo-academic">
  <meta name="generator" content="Hugo 0.36" />
  <meta name="author" content="Zepeng Mu">

  
  
  
  
    
      
    
  
  <meta name="description" content="Background: Platinum (Pt) is detectable for years after cisplatin treatment completion, but few studies have examined the extent of long-term exposure to Pt and associated co-morbidities. Methods: Eligible testicular cancer survivors (TCS, n = 633) given 300 or 400 ± 15 mg/m2 cisplatin underwent lab tests and extensive audiometry, and completed questionnaires at follow-up (median 5 y, range 1-35). Since subject-level PK parameters cannot be estimated in cross-sectional designs, we regressed log(Pt) on dose and follow-up time in the entire cohort. Each subject’s PK trait was defined as the deviation from the average concentration-time curve (the residual). High values indicate Pt levels exceeding the expected value, i.e. slower elimination. The Pt reference interval (RI) used (central 95 % of 147 non-Pt exposed patients) was 8-47 ng/L (JALM 2016; 1:2, 143). Linear regression at α = 0.05 was used for associations with co-morbidities. Hearing loss was quantified as the geometric mean of thresholds: 4-12 kHz (JCO 2016; 34, 2712). Sensory neuropathy was self-reported using EORTC-CIPN20. Cardiovascular (CV) burden was defined as angina, angioplasty, stroke, DVT, PE, CAD, and/or MI &gt; 1 month after therapy. Serum Pt, LDL, HDL, and creatinine (used to estimate creatinine clearance [CrCl] with the Cockroft-Gault formula) were measured. Results: Only 35 TCS (5.6 %) were within the RI (median follow-up for this group: 20 y, range: 10-35). The estimated time to reach RI upper limit was 18 and 21 y after 300 and 400 mg/m2 cisplatin respectively (time to RI median: 46 and 57 y). The Pt PK phenotype was strongly negatively associated with CrCl (p &lt; 10-9), and positively associated with age (p &lt; 10-8), neuropathy (p = 0.002; age-adjusted p = 0.04), and HDL (age-adjusted p &lt; 0.001). When adjusted for age, no associations were apparent with LDL, CV burden, or hearing loss. Conclusions: Circulating Pt persists for decades and may contribute to adverse outcomes. We previously showed that hearing loss, but not neuropathy, is associated with cumulative cisplatin dose. In conjunction with our findings here, this suggests differential kinetics of ototoxicity and neurotoxicity.">

  
  <link rel="alternate" hreflang="en-us" href="/publication/asco_dolan2018/">

  


  

  
  
  <meta name="theme-color" content="#0095eb">
  
  
  
  
    
  
  
    
    
      
        <link rel="stylesheet" href="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/styles/github.min.css">
      
    
  
  
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/css/bootstrap.min.css" integrity="sha512-6MXa8B6uaO18Hid6blRMetEIoPqHf7Ux1tnyIQdpt9qI5OACx7C+O3IVTr98vwGnlcg0LOLa02i9Y1HpVhlfiw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/academicons/1.8.1/css/academicons.min.css" integrity="sha512-NThgw3XKQ1absAahW6to7Ey42uycrVvfNfyjqcFNgCmOCQ5AR4AO0SiXrN+8ZtYeappp56lk1WtvjVmEa+VR6A==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/font-awesome/4.7.0/css/font-awesome.min.css" integrity="sha512-SfTiTlX6kk+qitfevl/7LibUOeJWlt9rbyDn92a1DqWOw9vWG2MFoays0sgObmWazO5BQPiFucnnEAjpAB+/Sw==" crossorigin="anonymous">
  <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.css" integrity="sha256-ygkqlh3CYSUri3LhQxzdcm0n1EQvH2Y+U5S2idbLtxs=" crossorigin="anonymous">
  
  
  
  
  <link rel="stylesheet" href="//fonts.googleapis.com/css?family=Montserrat:400,700%7cRoboto:400,400italic,700%7cRoboto&#43;Mono">
  
  <link rel="stylesheet" href="/styles.css">
  

  

  
  <link rel="alternate" href="/index.xml" type="application/rss+xml" title="HOME">
  <link rel="feed" href="/index.xml" type="application/rss+xml" title="HOME">
  

  <link rel="manifest" href="/site.webmanifest">
  <link rel="icon" type="image/png" href="/img/icon.png">
  <link rel="apple-touch-icon" type="image/png" href="/img/icon-192.png">

  <link rel="canonical" href="/publication/asco_dolan2018/">

  <meta property="twitter:card" content="summary_large_image">
  
  <meta property="twitter:site" content="@MZepeng">
  <meta property="twitter:creator" content="@MZepeng">
  
  <meta property="og:site_name" content="HOME">
  <meta property="og:url" content="/publication/asco_dolan2018/">
  <meta property="og:title" content="Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment | HOME">
  <meta property="og:description" content="Background: Platinum (Pt) is detectable for years after cisplatin treatment completion, but few studies have examined the extent of long-term exposure to Pt and associated co-morbidities. Methods: Eligible testicular cancer survivors (TCS, n = 633) given 300 or 400 ± 15 mg/m2 cisplatin underwent lab tests and extensive audiometry, and completed questionnaires at follow-up (median 5 y, range 1-35). Since subject-level PK parameters cannot be estimated in cross-sectional designs, we regressed log(Pt) on dose and follow-up time in the entire cohort. Each subject’s PK trait was defined as the deviation from the average concentration-time curve (the residual). High values indicate Pt levels exceeding the expected value, i.e. slower elimination. The Pt reference interval (RI) used (central 95 % of 147 non-Pt exposed patients) was 8-47 ng/L (JALM 2016; 1:2, 143). Linear regression at α = 0.05 was used for associations with co-morbidities. Hearing loss was quantified as the geometric mean of thresholds: 4-12 kHz (JCO 2016; 34, 2712). Sensory neuropathy was self-reported using EORTC-CIPN20. Cardiovascular (CV) burden was defined as angina, angioplasty, stroke, DVT, PE, CAD, and/or MI &gt; 1 month after therapy. Serum Pt, LDL, HDL, and creatinine (used to estimate creatinine clearance [CrCl] with the Cockroft-Gault formula) were measured. Results: Only 35 TCS (5.6 %) were within the RI (median follow-up for this group: 20 y, range: 10-35). The estimated time to reach RI upper limit was 18 and 21 y after 300 and 400 mg/m2 cisplatin respectively (time to RI median: 46 and 57 y). The Pt PK phenotype was strongly negatively associated with CrCl (p &lt; 10-9), and positively associated with age (p &lt; 10-8), neuropathy (p = 0.002; age-adjusted p = 0.04), and HDL (age-adjusted p &lt; 0.001). When adjusted for age, no associations were apparent with LDL, CV burden, or hearing loss. Conclusions: Circulating Pt persists for decades and may contribute to adverse outcomes. We previously showed that hearing loss, but not neuropathy, is associated with cumulative cisplatin dose. In conjunction with our findings here, this suggests differential kinetics of ototoxicity and neurotoxicity.">
  <meta property="og:locale" content="en-us">
  
  <meta property="article:published_time" content="2018-07-01T00:00:00&#43;00:00">
  
  <meta property="article:modified_time" content="2018-07-01T00:00:00&#43;00:00">
  

  

  <title>Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment | HOME</title>

</head>
<body id="top" data-spy="scroll" data-target="#toc" data-offset="71" >

<nav class="navbar navbar-default navbar-fixed-top" id="navbar-main">
  <div class="container">

    
    <div class="navbar-header">
      
      <button type="button" class="navbar-toggle collapsed" data-toggle="collapse"
              data-target=".navbar-collapse" aria-expanded="false">
        <span class="sr-only">Toggle navigation</span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
        <span class="icon-bar"></span>
      </button>
      
      <a class="navbar-brand" href="/">HOME</a>
    </div>

    
    <div class="collapse navbar-collapse">

      
      
      <ul class="nav navbar-nav navbar-left">
        

        
        
        
        
        
          
        

        <li class="nav-item">
          <a href="/publication">
            
            <span>Publications</span>
            
          </a>
        </li>

        
        

        
        
        
        
        

        <li class="nav-item">
          <a href="/cv/">
            
            <span>CV</span>
            
          </a>
        </li>

        
        

        
        
        
        
        

        <li class="nav-item">
          <a href="/fun">
            
            <span>Fun</span>
            
          </a>
        </li>

        
        
      

      
      </ul>

    </div>
  </div>
</nav>

<div class="pub" itemscope itemtype="http://schema.org/CreativeWork">

  


  <div class="article-container">
    <h1 itemprop="name">Pharmacokinetic (PK) modeling of serum platinum to reveal extent of long-term exposure and associated comorbidities after cisplatin treatment</h1>
    <span class="pub-authors" itemprop="author">
      
      El Charif, Omar, Mu, Zepeng, Gamazon, Eric R, et. al
      
    </span>
    <span class="pull-right">
      
<div class="share-box" aria-hidden="true">
  <ul class="share">
    <li>
      <a class="twitter"
         href="https://twitter.com/intent/tweet?text=Pharmacokinetic%20%28PK%29%20modeling%20of%20serum%20platinum%20to%20reveal%20extent%20of%20long-term%20exposure%20and%20associated%20comorbidities%20after%20cisplatin%20treatment&amp;url=%2fpublication%2fasco_dolan2018%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-twitter"></i>
      </a>
    </li>
    <li>
      <a class="facebook"
         href="https://www.facebook.com/sharer.php?u=%2fpublication%2fasco_dolan2018%2f"
         target="_blank" rel="noopener">
        <i class="fa fa-facebook"></i>
      </a>
    </li>
    <li>
      <a class="linkedin"
         href="https://www.linkedin.com/shareArticle?mini=true&amp;url=%2fpublication%2fasco_dolan2018%2f&amp;title=Pharmacokinetic%20%28PK%29%20modeling%20of%20serum%20platinum%20to%20reveal%20extent%20of%20long-term%20exposure%20and%20associated%20comorbidities%20after%20cisplatin%20treatment"
         target="_blank" rel="noopener">
        <i class="fa fa-linkedin"></i>
      </a>
    </li>
    <li>
      <a class="weibo"
         href="http://service.weibo.com/share/share.php?url=%2fpublication%2fasco_dolan2018%2f&amp;title=Pharmacokinetic%20%28PK%29%20modeling%20of%20serum%20platinum%20to%20reveal%20extent%20of%20long-term%20exposure%20and%20associated%20comorbidities%20after%20cisplatin%20treatment"
         target="_blank" rel="noopener">
        <i class="fa fa-weibo"></i>
      </a>
    </li>
    <li>
      <a class="email"
         href="mailto:?subject=Pharmacokinetic%20%28PK%29%20modeling%20of%20serum%20platinum%20to%20reveal%20extent%20of%20long-term%20exposure%20and%20associated%20comorbidities%20after%20cisplatin%20treatment&amp;body=%2fpublication%2fasco_dolan2018%2f">
        <i class="fa fa-envelope"></i>
      </a>
    </li>
  </ul>
</div>


    </span>

    

    
    <h3>Abstract</h3>
    <p class="pub-abstract" itemprop="text">Background: Platinum (Pt) is detectable for years after cisplatin treatment completion, but few studies have examined the extent of long-term exposure to Pt and associated co-morbidities. Methods: Eligible testicular cancer survivors (TCS, n = 633) given 300 or 400 ± 15 mg/m2 cisplatin underwent lab tests and extensive audiometry, and completed questionnaires at follow-up (median 5 y, range 1-35). Since subject-level PK parameters cannot be estimated in cross-sectional designs, we regressed log(Pt) on dose and follow-up time in the entire cohort. Each subject’s PK trait was defined as the deviation from the average concentration-time curve (the residual). High values indicate Pt levels exceeding the expected value, i.e. slower elimination. The Pt reference interval (RI) used (central 95 % of 147 non-Pt exposed patients) was 8-47 ng/L (JALM 2016; 1:2, 143). Linear regression at α = 0.05 was used for associations with co-morbidities. Hearing loss was quantified as the geometric mean of thresholds: 4-12 kHz (JCO 2016; 34, 2712). Sensory neuropathy was self-reported using EORTC-CIPN20. Cardiovascular (CV) burden was defined as angina, angioplasty, stroke, DVT, PE, CAD, and/or MI &gt; 1 month after therapy. Serum Pt, LDL, HDL, and creatinine (used to estimate creatinine clearance [CrCl] with the Cockroft-Gault formula) were measured. Results: Only 35 TCS (5.6 %) were within the RI (median follow-up for this group: 20 y, range: 10-35). The estimated time to reach RI upper limit was 18 and 21 y after 300 and 400 mg/m2 cisplatin respectively (time to RI median: 46 and 57 y). The Pt PK phenotype was strongly negatively associated with CrCl (p &lt; 10-9), and positively associated with age (p &lt; 10-8), neuropathy (p = 0.002; age-adjusted p = 0.04), and HDL (age-adjusted p &lt; 0.001). When adjusted for age, no associations were apparent with LDL, CV burden, or hearing loss. Conclusions: Circulating Pt persists for decades and may contribute to adverse outcomes. We previously showed that hearing loss, but not neuropathy, is associated with cumulative cisplatin dose. In conjunction with our findings here, this suggests differential kinetics of ototoxicity and neurotoxicity.</p>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Type</div>
          <div class="col-xs-12 col-sm-9">
            
            <a href="/publication/#1">
              Conference paper
            </a>
            
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    
    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Publication</div>
          <div class="col-xs-12 col-sm-9">Journal of Clinical Oncology</div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>
    

    <div class="row">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading">Date</div>
          <div class="col-xs-12 col-sm-9" itemprop="datePublished">
            July, 2018
          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="row" style="padding-top: 10px">
      <div class="col-sm-1"></div>
      <div class="col-sm-10">
        <div class="row">
          <div class="col-xs-12 col-sm-3 pub-row-heading" style="line-height:34px;">Links</div>
          <div class="col-xs-12 col-sm-9">

            




<a class="btn btn-primary btn-outline" href="http://ascopubs.org/doi/pdf/10.1200/JCO.2018.36.15_suppl.10058" target="_blank" rel="noopener">
  PDF
</a>
















          </div>
        </div>
      </div>
      <div class="col-sm-1"></div>
    </div>
    <div class="visible-xs space-below"></div>

    <div class="space-below"></div>

    <div class="article-style"></div>

    


  </div>
</div>



<footer class="site-footer">
  <div class="container">
    <p class="powered-by">

      &copy; 2018 &middot; 

      Powered by the
      <a href="https://sourcethemes.com/academic/" target="_blank" rel="noopener">Academic theme</a> for
      <a href="https://gohugo.io" target="_blank" rel="noopener">Hugo</a>.

      <span class="pull-right" aria-hidden="true">
        <a href="#" id="back_to_top">
          <span class="button_icon">
            <i class="fa fa-chevron-up fa-2x"></i>
          </span>
        </a>
      </span>

    </p>
  </div>
</footer>


<div id="modal" class="modal fade" role="dialog">
  <div class="modal-dialog">
    <div class="modal-content">
      <div class="modal-header">
        <button type="button" class="close btn-large" data-dismiss="modal">&times;</button>
        <h4 class="modal-title">Cite</h4>
      </div>
      <div>
        <pre><code class="modal-body tex"></code></pre>
      </div>
      <div class="modal-footer">
        <a class="btn btn-primary btn-outline js-copy-cite" href="#" target="_blank">
          <i class="fa fa-copy"></i> Copy
        </a>
        <a class="btn btn-primary btn-outline js-download-cite" href="#" target="_blank">
          <i class="fa fa-download"></i> Download
        </a>
        <div id="modal-error"></div>
      </div>
    </div>
  </div>
</div>

    

    
    

    

    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery/3.2.1/jquery.min.js" integrity="sha512-3P8rXCuGJdNZOnUx/03c1jOTnMn3rP63nBip5gOP2qmUh5YAdVAvFZ1E+QLZZbC1rtMrQb+mah3AfYW11RUrWA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.imagesloaded/4.1.3/imagesloaded.pkgd.min.js" integrity="sha512-umsR78NN0D23AzgoZ11K7raBD+R6hqKojyBZs1w8WvYlsI+QuKRGBx3LFCwhatzBunCjDuJpDHwxD13sLMbpRA==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/twitter-bootstrap/3.3.7/js/bootstrap.min.js" integrity="sha512-iztkobsvnjKfAtTNdHkGVjAYTrrtlC7mGp/54c40wowO7LhURYl3gVzzcEqGl/qKXQltJ2HwMrdLcNUdo+N/RQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/jquery.isotope/3.0.4/isotope.pkgd.min.js" integrity="sha512-VDBOIlDbuC4VWxGJNmuFRQ0Li0SKkDpmGyuhAG5LTDLd/dJ/S0WMVxriR2Y+CyPL5gzjpN4f/6iqWVBJlht0tQ==" crossorigin="anonymous"></script>
    <script src="https://cdnjs.cloudflare.com/ajax/libs/fancybox/3.2.5/jquery.fancybox.min.js" integrity="sha256-X5PoE3KU5l+JcX+w09p/wHl9AzK333C4hJ2I9S5mD4M=" crossorigin="anonymous"></script>
    
    
    <script src="/js/hugo-academic.js"></script>
    

    
    
      
      
      <script src="//cdnjs.cloudflare.com/ajax/libs/highlight.js/9.12.0/highlight.min.js" integrity="sha256-/BfiIkHlHoVihZdc6TFuj7MmJ0TWcWsMXkeDFwhi0zw=" crossorigin="anonymous"></script>
      

      

      

      <script>hljs.initHighlightingOnLoad();</script>
    

    
    
    <script type="text/x-mathjax-config">
        MathJax.Hub.Config({ tex2jax: { inlineMath: [['$','$'], ['\\(','\\)']] } });
    </script>
    
    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS_CHTML" integrity="sha512-tOav5w1OjvsSJzePRtt2uQPFwBoHt1VZcUq8l8nm5284LEKE9FSJBQryzMBzHxY5P0zRdNqEcpLIRVYFNgu1jw==" crossorigin="anonymous"></script>
    
    

  </body>
</html>

